What’s the risk of dying from AstraZeneca related Blood Clots?
In Australia, mortality of TTS is now down to around 4%.
This is a low risk of dying from a syndrome with a small likelihood of occurring. So we can express TTS risk in another way.
Two people in Australia have died from TTS after 3.8 million doses of the AstraZeneca vaccine delivered. This makes the likelihood of death from this syndrome about 0.5 in a million, or if you prefer whole numbers, about 1 in 2 million.
Perhaps even more visually powerful is to compare the risk of death from TTS to other risks we face in our lives, using a risk scale. This allows you to compare a range of risks and put them into perspective.
As the risk of TTS is a one-off risk normally associated with the first dose of the AstraZeneca vaccine, one interesting comparison is with other one-off risks, such as adventure sports. eg mountain climbing is 14 per million
Comparing this to being struck by lightening, the odds are about the same.
So the risk of death from TTS after the first dose of the AstraZeneca vaccine is similar to the risk of being killed by lightning in a year in Australia. And this pales in comparison when compared to other risks, such as the risk of dying in a car accident.
Pfizer also has it side effects:
Myocarditis and Pericarditis are now linked to the Pfizer vaccine. The CDC said it had recorded 1226 reports of myocarditis – inflammation of the heart – following mRNA vaccination. That amounts to 40.6 cases per million or 1 case in 25,000 which is 3 times higher that the rate of blood clots with AstraZeneca.
All patients administered the Pfizer vaccine should be warned of the symptoms of myocarditis/pericarditis, including chest pain, palpitations, syncope and shortness of breath or pain when breathing, ATAGI says. While the typical time to onset is 1-5 days after inoculation , including Moderna’s mRNA. The average age of affected patients was 36, and the average time to symptom onset was 3.5 days.
In contrast, pericarditis occurred 15 times after a first dose and 22 times after a second dose. The average age of affected patients was 59. 75% of affected patients were male.
the federal Department of Health said it was working with Pfizer to update the product information “to include myocarditis and pericarditis as an adverse effect identified through post-marketing experience and to add a warning statement.”